PDF icon Download PDF
Dtsch Med Wochenschr 2003; 128(24): 1353-1356
DOI: 10.1055/s-2003-39970
Arzneistoff
© Georg Thieme Verlag Stuttgart · New York

Risperidon

RisperidoneO. Zolk1 , N. Thürauf2
  • 1Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg
  • 2Klinik mit Poliklinik für Psychiatrie und Psychotherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg
Further Information

Publication History

eingereicht: 10.10.2002

akzeptiert: 17.4.2003

Publication Date:
12 June 2003 (online)

Also available ateRef
   Permissions and Reprints
Preview

Risperidon (Risperdal®), ein zur chemischen Klasse der Benzisoxazol-Derivate gehörender Serotonin-Dopamin-Rezeptorantagonist, wurde 1994 in Deutschland nach Clozapin als zweites atypisches Neuroleptikum zur Behandlung schizophrener Störungen eingeführt.

Literatur

  • 1 Kinon B J, Lieberman J A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis.  Psychopharmacology. 1996;  124 2-34
    Search in Google Scholar
  • 2 Product Information: Risperdal(R), risperidone. Janssen Pharmaceutica Inc., Titusville, NJ, USA 2002
    Search in Google Scholar
  • 3 Fachinformation: Risperdal Consta(R),. Janssen-Cilag GmbH, Neuss 2002
    Search in Google Scholar
  • 4 Yasui-Furukori N, Hidestrand M, Spina E, Facciola G, Scordo M G, Tybring G. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes.  Drug Metab Dispos. 2001;  29 1263-1268
    Search in Google Scholar
  • 5 Nyberg S, Dahl M L, Halldin C. A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone.  Psychopharmacology (Berl). 1995;  119 345-348
    Search in Google Scholar
  • 6 Scordo M G, Spina E, Facciola G, Avenoso A, Johansson I, Dahl M L. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.  Psychopharmacology. 1999;  147 300-305
    Search in Google Scholar
  • 7 Praxisleitlinien in Psychiatrie und Psychotherapie, Band 6, Behandlungsleitlinie Psychopharmakotherapie,. Falkai, Steinkopf Darmstadt Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde DGPPN (Hrsg.), Redaktion: W. Gaebel, P 2003
    Search in Google Scholar
  • 8 Kopala L C, Honer W G. Schizophrenia and severe tardive dyskinesia responsive to risperidone.  J Clin Psychopharmacol. 1994;  14 430-431
    Search in Google Scholar
  • 9 Rangwani S R, Gupta S, Burke W J, Potter J. Improvement of debilitating tardive dyskinesia with risperidone.  Ann Clin Psychiatry. 1996;  8 27-29
    Search in Google Scholar
  • 10 Czaplinski A, Steck A J, Fuhr P. Tic syndrome.  Neurol Neurochir Pol. 2002;  36 493-504
    Search in Google Scholar
  • 11 Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients.  J Clin Psychopharmacol. 1999;  19 101-103
    Search in Google Scholar
  • 12 Evidente V G, Gwinn-Hardy K, Caviness J N, Alder C H. Risperidone is effective in severe hemichorea/hemiballismus.  Mov Disord. 1999;  14 377-379
    Search in Google Scholar
  • 13 Kossoff E H, Singer H S. Tourette syndrome: clinical characteristics and current management strategies.  Paediatr Drugs. 2001;  3 355-363
    Search in Google Scholar
  • 14 Sindo I, Jorgensen J I. Treatment of tics in Tourette syndrome with atypical antipsychotic drugs.  Ugeskr Laeger. 2002;  164 3755-3759
    Search in Google Scholar
  • 15 Marder S R, Davis J M, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.  J Clin Psychiatry. 1997;  58 538-546
    Search in Google Scholar
  • 16 de Oliveira I R, Miranda-Scippa A M, de Sena E P, Pereira E L, Ribeiro M G, de Castro-e-Silva E, Bacaltchuk J. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety.  J Clin Pharm Ther. 1996;  21 349-358
    Search in Google Scholar
  • 17 Llorca P M, Chereau I, Bayle F J, Lancon C. Tardive dyskinesias and antipsychotics: a review.  Eur Psychiatry. 2002;  17 129-138
    Search in Google Scholar
  • 18 Möller H J, Bäuml J, Ferrero F, Fuger J, Geretsegger C, Kasper S, Kissling W, Schubert H. Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland.  Eur Arch Psychiatry Clin Neurosci. 1997;  247 291-296
    Search in Google Scholar
  • 19 Davis J M, Chen N. Clinical profile of an atypical antipsychotic: risperidone.  Schizophr Bull. 2002;  28 43-61
    Search in Google Scholar
  • 20 Tran P V, Hamilton S H, Kuntz A J, Potvin J H, Andersen S W, Beasley C, Tollefson G D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.  J Clin Psychopharmacol. 1997;  17 407-418
    Search in Google Scholar
  • 21 Edgell E T, Andersen S W, Johnstone B M, Dulisse B, Revicki D, Breier A. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.  Pharmacoeconomics. 2000;  18 567-579
    Search in Google Scholar
  • 22 Ho B C, Miller D, Nopoulos P, Andreasen N C. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.  J Clin Psychiatry. 1999;  60 658-663
    Search in Google Scholar
  • 23 Bilder R M, Goldman R S, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer J P, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper T B, Horowitz T L, Lieberman J A. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.  Am J Psychiatry. 2002;  159 1018-1028
    Search in Google Scholar
  • 24 Csernansky J G, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.  N Engl J Med. 2002;  346 16-22
    Search in Google Scholar
  • 25 Zhang X Y, Zhou D F, Cao L Y, Zhang P Y, Wu G Y, Shen Y C. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study.  Int Clin Psychopharmacol. 2001;  16 325-330
    Search in Google Scholar
  • 26 Glassman A H, Bigger J T. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.  Am J Psychiatry. 2001;  158 1774-1782
    Search in Google Scholar
  • 27 Finkel B, Lerner A G, Oyffe I, Sigal M. Risperidone-associated agranulocytosis.  Am J Psychiatry. 1998;  155 855-856
    Search in Google Scholar
  • 28 Wetterling T, Mussigbrodt H E. Weight gain: side effect of atypical neuroleptics?.  J Clin Psychopharmacol. 1999;  19 316-321
    Search in Google Scholar
  • 29 Ono S, Mihara K, Suzuki A, Kondo T, Yasui-Furukori N, Furukori H, De Vries R, Kaneko S. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes.  Psychopharmacology. 2002;  162 50-54
    Search in Google Scholar
  • 30 Spina E, Avenoso A, Scordo M G, Ancione M, Madia A, Gatti G, Perucca E. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.  J Clin Psychopharmacol. 2002;  22 419-423
    Search in Google Scholar
  • 31 Gianfrancesco F, Durkin M B, Mahmoud R, Wang R H. Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents.  Pharmacoeconomics. 2002;  20 413-427
    Search in Google Scholar
  • 32 Naber D, Lambert M, Krausz M. Atypische Neuroleptika in der Behandlung schizophrener Psychosen. UNI-MED, Bremen 1999
    Search in Google Scholar
  • 33 DeVane C L, Nemeroff C B. An evaluation of risperidone drug interactions.  J Clin Psychopharmacol. 2001;  21 408-416
    Search in Google Scholar
  • 34 Hiemke C, Weigmann H, Härtter S. Interaktionen selektiver Serotonin-Wiederaufnahmehemmer mit Neuroleptika. Georg Thieme Verlag In: König F, Kaschka WP. Interaktionen und Wirkmechanismen ausgewählter Psychopharmaka 2000
    Search in Google Scholar

Dr. med. Oliver Zolk

Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg

Fahrstraße 17

91054 Erlangen

Phone: 09131/8522783

Fax: 09131/8522773

Email: Zolk@pharmakologie.uni-erlangen.de